GBT
Tokenize Open Public Research Kirlian
Electrophotography
Phase
I Update
-
Techniques
Research
San Diego, CA --
December 1, 2020 -- InvestorsHub NewsWire
-- GBT Technologies Inc.
(OTC
PINK: GTCH)
("GBT", or the "Company"), announced
as
a
further update to its press
release issued
November
12, 2020,
that
GBT
Tokenize
("GBT/Tokenize"), its joint
venture, started Phase I in
the Kirlian
Electrophotography
imaging technique, potentially aimed for inclusion within its qTerm
device. Kirlian
photography
is
a series
of techniques that are based on the phenomenon known as electrical
coronal discharge. Images that are taken using these techniques
present a colorful so-called
aura, which can be
interpreted in a variety of ways.
The
open
research is focused on
the
efforts combining
Kirlian
imaging
with the use of machine learning technology to possibly detect
early disease symptoms. GBT/Tokenize
is
conducting
experiments
with a
few advanced algorithms, one of them
is a
private derivative of
the Genetic algorithm. The
genetic algorithm is a method for solving both constrained and
unconstrained optimization problems that are based on natural
selection, the process that drives biological
evolution. The algorithm
is planned to find pattern similarities in Kirlian
images in
living tissues in order to categorize potential health related
issues. Kirlian
imaging
produces typical features such as graphical protuberances, halos,
and discharge patterns, which can be analyzed by an AI computer
program as unique patterns, and categorized as possible
criteria for early symptoms
identification.
GBT/Tokenize
is
conducting
experiments
with
advanced algorithms and methods to analyze energy fields generated
by living organs at set periods. These image's auras will be
graphically analyzed to determine
patterns that are associated with possible health related symptoms.
GBT/Tokenize plans to develop
neural network based pattern recognition technology to
detect-and-associate unique patterns with related, possible health
issues. The research is
planned to be conducted over a period of one year and based on its
results the company will evaluate the feasibility of
implementation of
such techniques within its qTerm human vitals product in order to
provide further health information for the
user's
benefit.
"We are going to look
deeper into Kirilian
electrophotography
science, trying to identify the possibility of
detecting early disease symptoms. Kirlian
images
of a living
tissue during various intervals may exhibit some similarities. If
we could graphically analyze these images using machine learning
technology, reaching some consistent conclusions, then we may find
a way to find possible early health issue identification"
stated
Danny
Rittman, GBT's
CTO.
"We
intend to analyze and measure Kirilian images
to find unique patterns that may be associated with early symptoms.
We will look for full and partial similarities, repetitions,
or atypical auras patterns. We will be using AI computing power to
detect dynamic images changes as each image will be digitized using
high resolution scanning. Here the power of huge data analysis will
be extremely beneficial. We plan to implement interactive
algorithms to analyze on-the-fly out-of-boundaries patterns to get
a comparative representation between the images. The challenging
part will be to associate the human body's various radiations
graphical representation, with health related issues. For this
purpose, we plan to use our
AI, vast data analysis capabilities, trying to assemble a reliable
algorithm to create an associative table that will
relate patterns
to a possible onset disease. Upon reaching conclusions
we
will evaluate the
potential
implementation of
this technology within our qTerm device to further advice users
about their health" continued Dr.
Rittman.
Actual
GBT/Tokenize's
Phase I
imaging (for presentation purposes only):
Forward-Looking
Statements
Certain statements
contained in this press release may constitute "forward-looking
statements".
Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors
as disclosed in our filings with the Securities and Exchange
Commission located at their website ( http://www.sec.gov).
In
addition to these factors, actual future performance, outcomes, and
results may differ materially because of more general factors
including (without limitation) general industry and market
conditions and growth rates, economic conditions, governmental and
public policy changes, the Company's ability to raise capital on
acceptable terms, if at all, the Company's successful development
of its products and the integration into its existing products and
the commercial acceptance of the Company's
products.
The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change.
However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact:
Dr. Danny
Rittman, CTO
press@gopherprotocol.com